Granulocyte-colony-stimulatory factor: A strong inhibitor of natural killer cell function

Transfusion

Volumn 51, Issue 2, 2011, Pages 293-305

  Schlahsa, Laura ^a   Jaimes, Yarúa ^a   Blasczyk, Rainer ^a   Figueiredo, Constaņca ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANZYME B; INTERLEUKIN 6; INTERLEUKIN 8; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DOWN REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; NATURAL KILLER CELL; NEUTROPENIA; NORMAL HUMAN; PHENOTYPE; POSITIVE FEEDBACK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CELL DIVISION; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DEPRESSION, CHEMICAL; GENE EXPRESSION REGULATION; GRAFT VS LEUKEMIA EFFECT; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANZYMES; HUMANS; KILLER CELLS, NATURAL; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR; RECOMBINANT PROTEINS;

EID: 79951617288     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02820.x     Document Type: Article

References (42)

1. Pan L, Bressler S, Cooke KR, Krenger W, Karandikar M, Ferrara JL,. Long-term engraftment, graft-vs.-host disease, and immunologic reconstitution after experimental transplantation of allogeneic peripheral blood cells from G-CSF-treated donors. Biol Blood Marrow Transplant 1996; 2: 126-33. (Pubitemid 126488209)
2. Lane TA, Law P, Maruyama M, Young D, Burgess J, Mullen M, Mealiffe M, Terstappen LW, Hardwick A, Moubayed M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275-82.
3. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, MacDonald JS,. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995; 13: 1323-7.
4. Ringden O, Labopin M, Gorin NC, Le Blanc K, Rocha V, Gluckman E, Reiffers J, Arcese W, Vossen JM, Jouet JP, Cordonnier C, Frassoni F,. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004; 22: 416-23. (Pubitemid 41079769)
5. Ringden OT, Le Blanc K, Remberger M,. Granulocyte and granulocyte-macrophage colony-stimulating factors in allografts: uses, misuses, misconceptions, and future applications. Exp Hematol 2005; 33: 505-12. (Pubitemid 40592166)
6. Gazitt Y,. Immunologic profiles of effector cells and peripheral blood stem cells mobilized with different hematopoietic growth factors. Stem Cells 2000; 18: 390-8.
7. Rutella S, Zavala F, Danese S, Kared H, Leone G,. Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol 2005; 175: 7085-91. (Pubitemid 41713399)
8. Morris ES, MacDonald KP, Kuns RD, Morris HM, Banovic T, Don AL, Rowe V, Wilson YA, Raffelt NC, Engwerda CR, Burman AC, Markey KA, Godfrey DI, Smyth MJ, Hill GR,. Induction of natural killer T cell-dependent alloreactivity by administration of granulocyte colony-stimulating factor after bone marrow transplantation. Nat Med 2009; 15: 436-41.
9. Tanaka J, Kobayashi S, Mori A, Ohta S, Yamamoto Y, Hashino S, Asaka M, Imamura M,. Immunophenotype of peripheral blood mononuclear cells and NK cell activity after allogeneic bone marrow transplantation using recombinant human granulocyte colony-stimulating factor. Acta Haematol 1999; 102: 196-8. (Pubitemid 30139388)
10. Pavletic ZS, Joshi SS, Pirruccello SJ, Tarantolo SR, Kollath J, Reed EC, Bierman PJ, Vose JM, Warkentin PI, Gross TG, Nasrati K, Armitage JO, Kessinger A, Bishop MR,. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant 1998; 21: 33-41. (Pubitemid 28043434)
11. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A,. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-100. (Pubitemid 34229476)
12. Ringden O, Karlsson H, Olsson R, Omazic B, Uhlin M,. The allogeneic graft-versus-cancer effect. Br J Haematol 2009; 147: 614-33.
13. Pende D, Marcenaro S, Falco M, Martini S, Bernardo ME, Montagna D, Romeo E, Cognet C, Martinetti M, Maccario R, Mingari MC, Vivier E, Moretta L, Locatelli F, Moretta A,. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009; 113: 3119-29.
14. Yu J, Venstrom JM, Liu XR, Pring J, Hasan RS, O'Reilly RJ, Hsu KC,. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood 2009; 113: 3875-84.
15. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O'Reilly RJ, Horowitz MM, Dupont B,. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105: 4878-84. (Pubitemid 40807317)
16. Bignon JD, Gagne K,. KIR matching in hematopoietic stem cell transplantation. Curr Opin Immunol 2005; 17: 553-9. (Pubitemid 41207961)
17. Farag SS, Fehniger T, Ruggeri L, Velardi A, Caligiuri MA,. Natural killer cells: biology and application in stem-cell transplantation. Cytotherapy 2002; 4: 445-6. (Pubitemid 35375310)
18. Ruggeri L, Mancusi A, Perruccio K, Burchielli E, Martelli MF, Velardi A,. Natural killer cell alloreactivity for leukemia therapy. J Immunother 2005; 28: 175-82. (Pubitemid 40593982)
19. Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH,. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 2004; 103: 2677-82. (Pubitemid 38393024)
20. Vago L, Forno B, Sormani MP, Crocchiolo R, Zino E, Di Terlizzi S, Lupo Stanghellini MT, Mazzi B, Perna SK, Bondanza A, Middleton D, Palini A, Bernardi M, Bacchetta R, Peccatori J, Rossini S, Roncarolo MG, Bordignon C, Bonini C, Ciceri F, Fleischhauer K,. Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 2008; 112: 3488-99.
21. Freedman MH, Bonilla MA, Fier C, Bolyard AA, Scarlata D, Boxer LA, Brown S, Cham B, Kannourakis G, Kinsey SE, Mori PG, Cottle T, Welte K, Dale DC,. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 2000; 96: 429-36. (Pubitemid 30463359)
22. Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B, Fier C, Freedman M, Kannourakis G, Kinsey S, Schwinzer B, Zeidler C, Welte K, Dale DC,; Severe Chronic Neutropenia International Registry. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006; 107: 4628-35. (Pubitemid 43882607)
23. Beekman R, Touw IP,. G-CSF and its receptor in myeloid malignancy. Blood 2010; 115: 531-6.
24. Freedman MH, Alter BP,. Malignant myeloid transformation in congenital forms of neutropenia. Isr Med Assoc J 2002; 4: 1011-4.
25. Kudo K, Nagai H, Numata S, Ichihara M, Kinoshita T, Horibe K, Kato K, Matsuyama T, Kodera Y, Kojima S,. Absence of mutations in the granulocyte colony-stimulating factor (G-CSF) receptor gene in patients with myelodysplastic syndrome/acute myeloblastic leukaemia occurring after treatment of aplastic anaemia with G-CSF. Br J Haematol 2000; 111: 656-8.
26. Bohlius J, Reiser M, Schwarzer G, Engert A,. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2004; CD003189.
27. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A,. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-9. (Pubitemid 29300166)
28. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB,. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-7.
29. Passweg JR, Stern M, Koehl U, Uharek L, Tichelli A,. Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant 2005; 35: 637-43. (Pubitemid 40520947)
30. Koehl U, Sorensen J, Esser R, Zimmermann S, Grüttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T, Schwabe D,. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis 2004; 33: 261-6. (Pubitemid 39446496)
31. Velardi A, Ruggeri L, Mancusi A, Aversa F, Christiansen FT,. Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia. Curr Opin Immunol 2009; 21: 525-30.
32. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A,. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002; 62: 6178-86. (Pubitemid 35244469)
33. Lopez-Botet M, Bellon T,. Natural killer cell activation and inhibition by receptors for MHC class I. Curr Opin Immunol 1999; 11: 301-7. (Pubitemid 29263958)
34. Byrd A, Hoffmann SC, Jarahian M, Momburg F, Watzl C,. Expression analysis of the ligands for the Natural Killer cell receptors NKp30 and NKp44. Plos One 2007; 2: e1339.
35. Sloand EM, Kim S, Maciejewski JP, Van Rhee F, Chaudhuri A, Barrett J, Young NS,. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 2000; 95: 2269-74. (Pubitemid 30167724)
36. Kitabayashi A, Hirokawa M, Hatano Y, Lee M, Kuroki J, Niitsu H, Miura AB,. Granulocyte colony-stimulating factor downregulates allogeneic immune responses by posttranscriptional inhibition of tumor necrosis factor-alpha production. Blood 1995; 86: 2220-7.
37. Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ,. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci U S A 1987; 84: 9233-7.
38. Walz A, Peveri P, Aschauer H, Baggiolini M,. Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem Biophys Res Commun 1987; 149: 755-61. (Pubitemid 18023044)
39. Nicola NA, Metcalf D,. Binding of 125I-labeled granulocyte colony-stimulating factor to normal murine hemopoietic cells. J Cell Physiol 1985; 124: 313-21. (Pubitemid 15042211)
40. Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C, Fowler KJ, Basu S, Zhan YF, Dunn AR,. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994; 84: 1737-46. (Pubitemid 24286121)
41. Henslee PJ, Thompson JS, Romond EH, Doukas MA, Metcalfe M, Marshall ME, MacDonald JS,. T cell depletion of HLA and haploidentical marrow reduces graft-versus-host disease but it may impair a graft-versus-leukemia effect. Transplant Proc 1987; 19 (1 Pt 3): 2701-6.
42. Barfield RC, Otto M, Houston J, Holladay M, Geiger T, Martin J, Leimig T, Gordon P, Chen X, Handgretinger R,. A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation. Cytotherapy 2004; 6: 1-6. (Pubitemid 38325113)